Disaggregated Revenues

12 Months Ended

Dec. 31, 2023

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):

	Years Ended December 31,
	2023		2022		2021
Net product sales
Qelbree	$	140,192	$	61,322	$	9,879
GOCOVRI	119,637		104,421		9,778
Oxtellar XR	113,404		115,345		110,708
Trokendi XR	94,336		261,221		304,817
APOKYN	75,083		75,305		99,233
Other(1)	31,281		31,818		33,089
Total net product sales	$	573,933	$	649,432	$	567,504
Royalty and licensing revenues	33,588		17,806		12,271
Total revenues	$	607,521	$	667,238	$	579,775

______________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

The Company recognized noncash royalty revenues of $4.0 million, $9.8 million, and $9.4 million for the years ended December 31, 2023, 2022, and 2021, respectively, pursuant to the Company's agreement with HC Royalty (see Note 2, Summary of Significant Accounting Policies).

Adjustments related to prior year sales in 2023, 2022, and 2021 have amounted to less than 1% of net product sales for each of the respective periods.

The following table shows the percentage of net product sales to total net product sales:

	Percentage of Net Product Sales
	Years Ended December 31,
	2023	2022	2021
Qelbree	24%	9%	2%
GOCOVRI	21%	16%	2%
Oxtellar XR	20%	18%	19%
Trokendi XR	16%	40%	54%
APOKYN	13%	12%	17%
Other(1)	6%	5%	6%
Total	100%	100%	100%

______________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.